Skip to content

A study to evaluate the efficacy and safety of THROZEN (Cough Drop Formulation) for the treatment of cough and sore throat.

A Single -blind, Randomized, Clinical Study of THROZEN (Cough Drop Formulation) for the treatment of cough and sore throat

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015547
Enrollment
120
Registered
2018-08-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J96-J99- Other diseases of the respiratory system

Interventions

Intervention1: THROZEN cough drop: It is a herbal cough drop comprising Anacyclus pyrethrum, zinc and menthol. Dose: One cough drop twice a day. Administration : Oral Total duration of Therapy: Two w

Sponsors

MKTS Global Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Human volunteers with cough and/or sore throat issues should be included Patient with sign and symptoms of viral or bacterial throat infection Patients between the age above 18 to 65 years from both sex Patients willing to sign an informed written consent and comply with visit schedules Patients must be able to communicate effectively with study personnel

Exclusion criteria

Exclusion criteria: Known positive status and known history for HIV, active hepatitis B or hepatitis C. Pregnant or breast feeding women Volunteers should not have any disease. Especially respiratory tract disorder and tuberculosis volunteers even with past historyshould not be included Subjects on any other experimental treatment within 07 days of the first dose of study drug or who have not recovered from the side effects of such therapy Patient have history of hospitalized treatment before 07 days Patient taking any other then investigational drug in last 07 days

Design outcomes

Primary

MeasureTime frame
Relief from soar throat and coughTimepoint: 14 days intervention study

Secondary

MeasureTime frame
Relief from nasal congetionTimepoint: 14 days intervention study

Countries

India

Contacts

Public ContactDr Manish A Rachchh

Accuprec Research Labs Pvt Ltd

rina.gokani@accuprec.com9099616769

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026